Browse EX-10 agreements

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO SCRIBE THERAPEUTICS INC. IF PUBLICLY DISCLOSED.

NOTICE OF AWARD – PDEV Awards: Funding Opportunity for Preclinical Stage Projects California Institute for Regenerative Medicine

Issue Date: 5/26/2026

 

Award Number:

  

PDEV-19150

  

Project Period Start:

  

2026-04-01

Awardee Name:

  

Scribe Therapeutics

  

Project Period End (estimated):

  

2029-09-30

Principal Investigator:

  

Brett Staahl

  

Total Award Amount:

  

$13,000,000

Project Title:

  

A first-in-class CRISPR-CasX gene editor silencing APOC3 transcription for the treatment of Severe Hypertriglyceridemia

 

Authorized Organizational Official and Address:

  

Electronic Remittance Advice will be sent to:

Sunny Mok

  

[*]

SVP of Operations

  

1150 Marina Village Pkwy

Alameda, CA 94501

…

Execution Copy

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO SCRIBE THERAPEUTICS INC. IF PUBLICLY DISCLOSED.

Development and Option Agreement

by and between

ACUITAS THERAPEUTICS, INC.

and

SCRIBE THERAPEUTICS INC.

dated

November 7, 2022

---

TABLE OF CONTENTS

 

 

 

 

 

  

Page

 

Article 1 Definitions

  

 

1

 

Article 2 Governance

  

 

9

 

2.1

 

Management

  

 

9

 

2.2

 

Joint Development Committee

  

 

9

 

Article 3 The Program

  

 

10

 

3.1

 

Program Generally

  

 

10

 

3.2

 

FTEs

  

 

12

 

3.3

 

Program Records, Reports and Materials

  

 

13

 

3.4

 

Program Licenses

  

 

14

 

Article 4 Reserved Targets

  

 

16

 

4.1

 

Generally

  

 

16

 

4.2

 

Reserved Protein Target List, Restricted Protein Target List and Protein Target Notices

  

 

16

 

4.3

 

Expiration of Pre-Existing Restrictions

  

 

17

 

4.4

 

Fees

  

 

17

…

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO SCRIBE THERAPEUTICS INC. IF PUBLICLY DISCLOSED.

UNIVERSITY OF CALIFORNIA, BERKELEY

OFFICE OF TECHNOLOGY LICENSING

 

 

 

AMENDED AND RESTATED EXCLUSIVE LICENSE AGREEMENT

BETWEEN

SCRIBE THERAPEUTICS INC.

AND

THE REGENTS OF THE UNIVERSITY OF CALIFORNIA

FOR

“RNA-GUIDED NUCLEIC ACID MODIFYING ENZYMES AND METHODS OF USE THEREOF (“CASX”)”

AND

“RNA-GUIDED NUCLEIC ACID MODIFYING ENZYMES AND METHODS OF USE THEREOF (“CASY”)

 

 

 

UC Case Nos.: BK-2017-016 & 2017-017,BK-2018-215 and BK-2019-011

---

Table of Contents

 

Article

 

 

  

Page

 

 

BACKGROUND

  

 

1

 

 

DEFINITIONS

  

 

3

 

 

GRANT

  

 

8

 

 

SUBLICENSES

  

 

9

 

 

LICENSE ISSUE FEE

  

 

12

 

 

ROYALTIES, MAINTENANCE FEES, MINIMUM ANNUAL ROYALTIES

  

 

15

 

 

DUE DILIGENCE

  

 

20

 

 

PROGRESS AND ROYALTY REPORTS

…

SCRIBE THERAPEUTICS INC.

2018 STOCK INCENTIVE PLAN

1. Purposes of the Plan. The purposes of this Plan are to attract and retain the best available personnel, to provide additional incentives to Employees, Directors and Consultants and to promote the success of the Company’s business.

2. Definitions. The following definitions shall apply as used herein and in the individual Award Agreements except as defined otherwise in an individual Award Agreement. In the event a term is separately defined in an individual Award Agreement, such definition shall supersede the definition contained in this Section 2.

(a) “Administrator” means the Board or any of the Committees appointed to administer the Plan.

(b) “Affiliate” and “Associate” shall have the respective meanings ascribed to such terms in Rule 12b-2 promulgated under the Exchange Act.

…

SCRIBE THERAPEUTICS INC.

SCIENTIFIC ADVISORY BOARD MEMBER AGREEMENT

This Scientific Advisory Board Member Agreement (this “Agreement”) is made and entered into as of April 12, 2021 (the “Effective Date”) by and between Scribe Therapeutics Inc., a Delaware corporation having an address at 150 Marina Village Pkwy, Alameda, CA 94501 (the “Company”), and David F. Savage (“Member”), an individual having an address at      .

WHEREAS, the Company desires to retain Member as an independent contractor to perform certain advisory services for the Company; and

WHEREAS, Member is willing to perform such services, on terms set forth more fully below.

NOW, THEREFORE, in consideration of the mutual promises contained herein, the parties hereby agree as follows:

1. SERVICES, CONSIDERATION AND NATURE OF SCIENTIFIC ADVISORY BOARD

…

This Share Subscription Agreement (this “Agreement”), dated as of June 30, 2026, by and between Lianhe Sowell International Group Ltd (the “Company”), Shenzhen Sowell Technology Development Co., Ltd (“Shenzhen Sowell”) and Lianyue Holding Limited (the “Subscriber”).

 

RECITALS:

WHEREAS, the Company desires to issue, sell and deliver to the Subscriber, and the Subscriber desires to purchase and acquire from the Company, upon the terms and conditions set forth in this Agreement, an aggregate of 2,400,000 Class B Ordinary Shares of par value US$0.0016 of the Company (the “Securities”).

 

NOW, THEREFORE, in consideration of the foregoing and representations, warranties, covenants and agreements set forth herein as well as other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged and accepted, and intending to be legally bound, the Company, Shenzhen Sowell and the Subscriber hereby agree as follows:

 

DEFINITIONS

…

EXECUTION VERSION

Commitment Increase and Maturity Extension Agreement

This Commitment Increase and Maturity Extension Agreement (this “Agreement”), dated as of June 26, 2026, is among Cheniere Energy, Inc., a Delaware corporation (the “Borrower”), Société Générale, as Administrative Agent (the “Administrative Agent”), each Lender listed as an “Additional Commitment Lender” on Schedule I hereto (the “Additional Commitment Lenders”, each an “Additional Commitment Lender”) and each Lender listed as an “Extending Lender” on Schedule II hereto (the “Extending Lenders”, each an “Extending Lender”).

Preliminary Statements

…

NETLIST, INC.

 

2026 PERFORMANCE EQUITY PLAN

 

DEFINITIONS.

 

Unless otherwise specified or unless the context otherwise requires, the following terms, as used in this Netlist, Inc. 2026 Performance Equity Plan, have the following meanings:

 

“Administrator” means the Board of Directors, unless it has delegated power to act on its behalf to the Committee, in which case the term “Administrator” means the Committee.

 

“Affiliate” means a corporation or other entity, which, for purposes of Section 424 of the Code, is a parent or subsidiary of the Company, direct or indirect.

 

“Agreement” means a written or electronic document setting forth the terms of a Stock Right delivered pursuant to the Plan, in such form as the Administrator shall approve.

 

“Board of Directors” means the Board of Directors of the Company.

…

Restricted Stock Unit No.________

 

NETLIST, INC.

 

Restricted Stock Unit Award Grant Notice

Restricted Stock Unit Award Grant under the Company’s

Netlist, Inc. 2026 Performance Equity Plan

 

Name:

 

 

 

 

Grant Number:

 

 

 

 

 

Grant Date:

 

 

 

 

 

Grant Type:

 

 

 

 

 

Grant Shares:

 

 

 

Vesting of Award:

This Restricted Stock Unit Award shall vest as follows provided the Participant is an Employee, director or Consultant of the Company or of an Affiliate on the applicable vesting date:

 

 

 

Number of Restricted Stock Units

 

Performance Goals

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

  

The Company and the Participant acknowledge receipt of this Restricted Stock Unit Award Grant Notice and agree to the terms of the Restricted Stock Unit Agreement attached hereto and incorporated by reference herein, the Company’s 2026 Performance Equity Plan and the terms of this Restricted Stock Unit Award as set forth above.

…

HTML Editor

Exhibit 10.1

 

FIRST AMENDMENT TO

AMENDED AND RESTATED EMPLOYMENT AGREEMENT

 

FIRST AMENDMENT, dated as of July 2, 2026 (the “Amendment”), to the Amended and Restated Employment Agreement (the “Employment Agreement”) dated as of February 3, 2025 by and between Farouq Tuweiq (“Executive”) and Bel Fuse, Inc., a New Jersey corporation (the “Company”). 

 

WHEREAS, the Company and Executive desire to memorialize certain changes to the compensation terms of the Employment Agreement approved by the Compensation Committee of the Board of Directors of the Company which are effective as of June 1, 2026;

 

NOW THEREFORE, in consideration of the promises and the mutual covenants and agreements contained herein and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto, intending to be legally bound hereby, agree as follows:

 

 

Base Salary.  Effective as of June 1, 2026, the Base Salary amount set forth in Section 4.1 of the Employment Agreement shall be $725,000.

 

 

…

HTML Editor

Exhibit 10.2

 

FIRST AMENDMENT TO EMPLOYMENT AGREEMENT

 

FIRST AMENDMENT, dated as of July 2, 2026 (the “Amendment”), to the Employment Agreement (the “Employment Agreement”) dated as of May 20, 2025 by and between Lynn Hutkin (“Executive”) and Bel Fuse, Inc., a New Jersey corporation (the “Company”). 

 

WHEREAS, the Company and Executive desire to memorialize certain changes to the compensation terms of the Employment Agreement approved by the Compensation Committee of the Board of Directors of the Company which are effective as of June 1, 2026;

 

NOW THEREFORE, in consideration of the promises and the mutual covenants and agreements contained herein and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto, intending to be legally bound hereby, agree as follows:

 

 

Base Salary.  Effective as of June 1, 2026, the Base Salary amount set forth in Exhibit A of the Employment Agreement (“Exhibit A”) shall be $400,000.

 

 

…

Document

Exhibit 10.1

Confidential Separation Agreement

This Separation and General Release Agreement (“Agreement”) is entered into on the date this Agreement becomes effective between Stacia Hansen (“You" or “Your”) and Arq, Inc. (hereinafter referred to as “the Company”). The Parties agree that this Agreement represents the full and complete agreement concerning all matters between them and the Parties intend to be legally bound by its terms.

WHEREAS, Your employment with the Company terminated effective June 12, 2026, (“Termination Date”).

NOW, THEREFORE, You and the Company agree as follows:

1.General: You will receive the following wages and benefits regardless of whether You sign this Agreement.

a)Salary: You will be paid Your current salary, as applicable, through Your Termination Date, as well as all earned but unused vacation.

b)Vested Benefits: Your rights to other Company benefits will continue to be determined by the terms of any applicable plans.

…